---
title: "Eli Lilly's Market Cap Balloons Again On This IPO's Setback"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291971712.md"
description: "On Tuesday, shares of Eli Lilly surged to an all-time high following disappointing test outcomes from newly listed IPO company, Kailera Therapeutics, regarding their weight-loss medication. This setback caused a significant increase in Eli Lilly's market capitalization."
datetime: "2026-07-07T19:45:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291971712.md)
  - [en](https://longbridge.com/en/news/291971712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291971712.md)
generator: "portal-rs"
---

# Eli Lilly's Market Cap Balloons Again On This IPO's Setback

On Tuesday, shares of Eli Lilly surged to an all-time high following disappointing test outcomes from newly listed IPO company, Kailera Therapeutics, regarding their weight-loss medication. This setback caused a significant increase in Eli Lilly's market capitalization.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)

## Related News & Research

- [Why Is Omniab Stock Rallying After Eli Lilly Deal?](https://longbridge.com/en/news/296113651.md)
- [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md)
- [Sarasin & Partners LLP Sells 11,349 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295214848.md)
- [Eli Lilly and Company (NYSE:LLY) Releases Quarterly Earnings Results, Beats Expectations By $2.32 EPS](https://longbridge.com/en/news/295054597.md)
- [Community Financial Services Group LLC Acquires 1,774 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295504105.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**